Faro Raises $37.3M Series B

Faro, based in San Diego, CA, is a software company providing structured data and AI infrastructure for clinical development. The company has announced the successful completion of a $37.3 million Series B funding round.

Investors

The round was co-led by Merck Global Health Innovation Fund and S32. Additional participating investors include General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital, Zetta, and Ankona Capital.

Faro Use of Funds

Faro will use the capital to expand its agentic AI capabilities and accelerate the deployment of its AI agents with customers. The funding supports the company's efforts to help pharmaceutical and biotechnology teams improve the quality and efficiency of clinical development workflows from first-in-human studies through regulatory approval.

About Faro

Faro provides a platform that translates complex scientific, medical, and operational concepts into structured, machine-readable intent. The company's platform is utilized by six of the world's ten largest pharmaceutical companies to design clinical studies, identify risks, and automate complex development lifecycles.

Funding Details

Company Website: https://faro.ai

Company: Faro
Raised: $37.3M
Round: Series B
Funding Date: August 26, 2026
Lead Investor: Merck Global Health Innovation Fund, S32
Additional Investors: General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital, Zetta, Ankona Capital
Company Website: https://faro.ai
Software Category: AI/Biotech Software
Source: https://markets.businessinsider.com/news/currencies/faro-raises-37-3m-series-b-to-scale-agentic-ai-across-clinical-development-1034201628